Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3847798 | 0.99 | ALDH1A1 (0.43) | ALDH1A1GSK3BGSK3ARAB9ASMN1; SMN2 | |
| SCHEMBL1820216 | 0.81 | ALDH1A1 (0.46) | ALDH1A1GSK3BGSK3ARAB9ASMN1; SMN2 | |
| Bromide SCHEMBL2954276 | 0.80 | ALDH1A1 (0.48) | ALDH1A1GSK3BGSK3ARAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL33828 | 0.80 | RAB9A (0.46) | ALDH1A1GSK3BGSK3ARAB9ASMN1; SMN2 | |
| SCHEMBL6535191 | 0.78 | ALDH1A1 (0.43) | ALDH1A1GSK3BGSK3ARAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3846709 | 0.77 | RAB9A (0.43) | ALDH1A1GSK3BGSK3ARAB9ASMN1; SMN2 | |
| SCHEMBL6937918 | 0.76 | ALDH1A1 (0.41) | ALDH1A1GSK3BGSK3ARAB9ASMN1; SMN2 | |
| Bromide SCHEMBL2947505 | 0.75 | ALDH1A1 (0.43) | ALDH1A1GSK3BGSK3ARAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3845136 | 0.73 | KMT2A (0.46) | ALDH1A1RAB9ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL6535060 | 0.72 | ALDH1A1 (0.43) | ALDH1A1GSK3BGSK3ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0808163-B1 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON INC (US) | 2003-07-23 | — | — | EP | claimed |
| US-6440749-B1 | ADMINISTERING A THIAZOLE COMPOUND | ALTEON. INC. | 2002-08-27 | — | — | US | claimed |
| US-6007865-A | FOR INHIBITING AND REVERSING NONENZYMATIC CROSS-LINKING (PROTEIN AGING), TREATING KIDNEY DAMAGE AND TREATING COMPLICATIONS OF DIABETES, PREVENTING FOOD SPOILAGE | ALTEON INC. | 1999-12-28 | — | — | US | claimed |
| US-20090088461-A1 | Methods of Treating or Preventing Cardiac Disease Associated With a High Fat Diet | SYNVISTA THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-20080132553-A1 | Preventing and reversing the formation of advance glycosylation endproducts | CERAMI ANTHONY | 2008-06-05 | — | — | US | disclosed |
| US-20070025926-A1 | Preventing and reversing the formation of advance glycosylation endproducts | SYNVISTA THERAPEUTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-7022719-B2 | Preventing and reversing the formation of advance glycosylation endproducts | ALTEON, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-6440749-B1 | ADMINISTERING A THIAZOLE COMPOUND | ALTEON. INC. | 2002-08-27 | — | — | US | disclosed |
| EP-0808163-A2 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON, INC. (US) | 1997-11-26 | — | — | EP | disclosed |
| WO-1996022095-A2 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON INC. (US) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088461-A1 | Methods of Treating or Preventing Cardiac Disease Associated With a High Fat Diet | FABP3, TXNRD2, PPARD | ALDH1A1 653/4885GSK3B 300/4885GSK3A 262/4885 |
| US-20080132553-A1 | Preventing and reversing the formation of advance glycosylation endproducts | AGER, PTMS, OGA | ALDH1A1 1576/4885GSK3B 1564/4885GSK3A 1466/4885 |
| US-20070025926-A1 | Preventing and reversing the formation of advance glycosylation endproducts | AGER, PTMS, OGA | ALDH1A1 1227/4885GSK3B 1229/4885GSK3A 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.